The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions

Intern Med. 2003 Sep;42(9):771-80. doi: 10.2169/internalmedicine.42.771.

Abstract

To date, in the investigation of the role of S. aureus in WG, we face a paradoxical situation. On the one hand, clinical results obtained from treatment of WG patients with co-trimoxazole and studies assessing the impact of S. aureus on disease relapses strongly suggest that this bacterium contributes to disease pathophysiology. On the other hand, laboratory investigation of the possible mechanisms by which S. aureus is involved in WG is scarce, despite the fact that knowledge and tools to study this microorganism are abundant. In the present review, we discuss recent works investigating the possible pathophysiologic contribution of S. aureus to WG. Moreover, we propose a number of possibly relevant pathways of interaction of this bacterium with lymphoid and nonlymphoid cells of the WG host.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / therapeutic use
  • Endothelium / immunology
  • Exotoxins / immunology*
  • Granulomatosis with Polyangiitis / drug therapy
  • Granulomatosis with Polyangiitis / immunology*
  • Granulomatosis with Polyangiitis / microbiology*
  • Granulomatosis with Polyangiitis / physiopathology
  • Humans
  • Leukocytes / immunology
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / immunology*
  • Staphylococcal Infections / physiopathology
  • Staphylococcus aureus / immunology*
  • Staphylococcus aureus / pathogenicity
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Anti-Infective Agents
  • Exotoxins
  • Trimethoprim, Sulfamethoxazole Drug Combination